Trevi Therapeutics (NASDAQ:TRVI - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $12.50 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 93.20% from the stock's current price. HC Wainwright also issued estimates for Trevi Therapeutics' Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at ($0.31) EPS.
Several other research firms also recently issued reports on TRVI. Needham & Company LLC reduced their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a report on Wednesday. Oppenheimer upped their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Finally, D. Boral Capital reissued a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Trevi Therapeutics currently has an average rating of "Buy" and a consensus price target of $17.56.
Read Our Latest Stock Analysis on Trevi Therapeutics
Trevi Therapeutics Trading Down 2.1 %
NASDAQ TRVI traded down $0.14 during trading hours on Wednesday, reaching $6.47. 3,742,537 shares of the company's stock were exchanged, compared to its average volume of 994,524. The firm has a fifty day moving average of $4.60 and a 200-day moving average of $3.76. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The stock has a market cap of $497.32 million, a PE ratio of -14.70 and a beta of 0.90.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. As a group, research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.
Insider Buying and Selling
In related news, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares of the company's stock, valued at approximately $519,075. This trade represents a 51.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 24.37% of the stock is currently owned by company insiders.
Institutional Trading of Trevi Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. increased its holdings in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after purchasing an additional 3,283,684 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Trevi Therapeutics during the 4th quarter worth about $17,099,000. Vivo Capital LLC increased its holdings in Trevi Therapeutics by 116.3% during the 4th quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after purchasing an additional 1,875,000 shares in the last quarter. Woodline Partners LP increased its holdings in Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after purchasing an additional 2,606,370 shares in the last quarter. Finally, MPM Bioimpact LLC increased its holdings in Trevi Therapeutics by 101.2% during the 4th quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company's stock worth $12,751,000 after purchasing an additional 1,556,379 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Further Reading
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
